PLUVICTO® Therapy at Mosaic Life Care
A Targeted Option for Advanced Prostate Cancer
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is a new type of targeted radioligand therapy for men with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). If you’ve already received certain prostate cancer therapy, PLUVICTO may be the next step in your treatment journey.
How PLUVICTO® Works
PLUVICTO is designed to deliver radiation directly to prostate cancer cells that express PSMA — a protein found on the surface of many prostate cancer cells. By binding to these cells, PLUVICTO delivers a precise dose of radiation to help destroy cancer while limiting damage to surrounding healthy tissue.
What to Expect During Treatment
- Treatment Schedule: PLUVICTO is given once every six weeks, for up to six doses.
- Administration: Each dose is delivered through an IV injection or infusion.
- Supportive Care: You’ll be cared for by a team of specialists, including oncologists, urologists, and nuclear medicine experts.
Before and After Each Dose
- Before Treatment: You may undergo imaging and lab tests to confirm eligibility and monitor your health.
- After Treatment: Your body may emit low levels of radiation. You’ll receive specific safety instructions, such as limiting close contact with others for a few days and staying well-hydrated to help flush out the radiation.
Is PLUVICTO Right for You?
PLUVICTO is approved for adults with PSMA-positive mCRPC who have already been treated with hormone certain prostate cancer therapy. Your doctor will use a special imaging scan to determine if your cancer expresses PSMA and if PLUVICTO is a good fit for your treatment plan.
